Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Squamous Cell Carcinoma of Head and Neck 1Pathologic Complete Response 1Ovarian Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Bevacizumab 56Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 31Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15Capecitabine 14HMPL-013 13Folfox protocol 13Gemcitabine 12Cisplatin 12trifluridine tipiracil drug combination 11Panitumumab 11Carboplatin 11Pemetrexed 9IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Educational Status 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Endoscopy × 90 days × Clear all
NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Emory University

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡